孕酮对OCTN2的抑制作用及对左旋肉碱肾脏排泄的影响

目的 考察孕酮对肉碱/有机阳离子转运体2(carnitine/organic cation transporter 2,OCTN2)功能的影响,并探讨其是否通过抑制肾脏OCTN2功能改变左旋肉碱肾脏排泄,从而降低妊娠期血浆左旋肉碱浓度。方法 采用已构建的稳定高表达人OCTN2的MDCK-hOCTN2细胞模型,分别以米屈肼和氘代左旋肉碱为底物,考察孕酮对OCTN2的抑制作用。正常雌性ICR小鼠皮下注射孕酮,使其达妊娠晚期血清孕酮浓度,比较其与对照组小鼠左旋肉碱尿液排泄差异,以及血浆和各组织中左旋肉碱浓度差异。结果 孕酮显著抑制OCTN2对米屈肼和氘代左旋肉碱的摄取,半数抑制浓度分别为8.7 μmol·L^-1和14.0 μmol·L^-1。孕酮给药组小鼠血清孕酮浓度为462~1153 nmol·L^-1,与妊娠晚期生理浓度相当,左旋肉碱的尿液排泄量以及血浆、肝脏、肾脏和心脏中左旋肉碱浓度与对照组无显著差异。结论 孕酮显著抑制OCTN2功能,但与妊娠晚期生理浓度相当的孕酮不影响左旋肉碱的肾脏排泄及体内稳态。     

人TIMP-2基因的克隆及其原核表达

目的 构建人TIMP-2重组表达载体,并在大肠杆菌BL21 (DE3)中表达.方法 提取人肝癌细胞(Hep G2)总RNA后,经RT-PCR扩增获得目的片段,插入克隆载体pMD18-T;酶切鉴定和测序后将TIMP-2导入原核表达载体pGEX-4T-1中,构建重组质粒pGEX-TIMP-2.将重组质粒转化至大肠杆菌菌株BL21 (DE3)中,IPTG诱导融合蛋白表达后用SDS-PAGE电泳检测并用western blot验证(蛋白质印迹法).结果 成功构建原核重组表达载体pGEX-TIMP-2,并在原核宿主BL21中大量表达融合蛋白GST-TIMP-2.结论 克隆人TIMP-2基因并在原核生物中大量表达.     

SARS病毒E2蛋白保护性抗原片段原核表达载体的构建及表达

为构建SARS病毒E2蛋白保护性抗原片段的原核表达载体，采用人工合成法合成SARS病毒E2蛋白3’端cDNA；用常规分子克隆方法将此cDNA片段克隆入原核表达载体pBV220中，经温度诱导和SDS-PAGE电泳证明外源蛋白表达。结果表明合成的E2蛋白cDNA经序列测定，与报道的SARS病毒相应序列一致，内切酶酶切及PCR均得到456bp的cDNA片段，与实验设计一致，证明此cDNA片段已插入pBV220载体中；SDS-PAGE电泳表明有外源蛋白表达。结论：用本文介绍的方法可成功地合成并克隆SARS病毒E2蛋自原核表达载体，此项研究结果为SARS的诊断和预防奠定了基础。     

EB病毒基因Z2A原核表达载体的构建及表达

目的 构建能分泌性表达EB病毒(Epstein-Barr virus,EBV)融合基因Z2A的BCG重组质粒并导入BCG.方法 分别以BCG和EBV融合基因cDNA为模板,通过PCR扩增得到139 bp的BCG-Ag85B信号肽序列和2291 bp的Z2A基因序列.将BCG-Ag85B信号肽序列与大肠杆菌-BCG穿梭表达载体pMV261重组,得到重组质粒pMVS.再将EBV融合基因序列Z2A亚克隆至pMVS中,得到重组质粒pMVZ2A,电转化导入BCG,采用十二烷基硫酸钠-聚丙烯酰胺凝胶电泳对表达产物进行分析.结果 构建的重组质粒pMVZ2A经双酶切、PCR扩增及序列测定证实,克隆基因BCG-Ag85B信号肽和Z2A正确插入载体pMV261.重组质粒pMVZ2A电转化导入BCG后能在BCG中有效表达相应蛋白.结论 构建的重组质粒pMVZ2A能在BCG中表达相应蛋白.这一结果为改造BCG及发展新型抗EBV和结核杆菌的双价疫苗奠定了基础.     

EB病毒基因Z2A原核表达载体的构建及表达

目的 构建能分泌性表达EB病毒(Epstein-Barr virus,EBV)融合基因Z2A的BCG重组质粒并导入BCG.方法 分别以BCG和EBV融合基因cDNA为模板,通过PCR扩增得到139 bp的BCG-Ag85B信号肽序列和2291 bp的Z2A基因序列.将BCG-Ag85B信号肽序列与大肠杆菌-BCG穿梭表达载体pMV261重组,得到重组质粒pMVS.再将EBV融合基因序列Z2A亚克隆至pMVS中,得到重组质粒pMVZ2A,电转化导入BCG,采用十二烷基硫酸钠-聚丙烯酰胺凝胶电泳对表达产物进行分析.结果 构建的重组质粒pMVZ2A经双酶切、PCR扩增及序列测定证实,克隆基因BCG-Ag85B信号肽和Z2A正确插入载体pMV261.重组质粒pMVZ2A电转化导入BCG后能在BCG中有效表达相应蛋白.结论 构建的重组质粒pMVZ2A能在BCG中表达相应蛋白.这一结果为改造BCG及发展新型抗EBV和结核杆菌的双价疫苗奠定了基础.     

人SMYD3基因原核表达载体的构建及在大肠杆菌中的表达

构建人SMYD3基因原核表达载体,并在大肠杆菌中诱导表达。通过PCR方法从重组质粒pcD-NA-SMYD3中扩增得到SMYD3基因,将其克隆入pGEX-6P-1原核表达载体。将重组质粒转化入E.coli Rosetta(DE3)中,以IPTG诱导融合蛋白表达。表达产物用SDS-PAGE及Western blotting分析鉴定。酶切鉴定和测序结果证明成功构建了重组表达载体pGEX-SMYD3。SDS-PAGE及Western blotting鉴定结果表明人SMYD3基因在大肠杆菌中获得了良好的表达。实验成功地构建了SMYD3基因原核表达载体并在大肠杆菌中获得良好表达,为进一步研究SMYD3蛋白功能奠定了基础。     

基因变构人白细胞介素-2克隆构建和原核表达

目的构建基因变构IL-2穴88N→R雪的重组克隆熏并将其在原核系统中进行高效表达,为研究基因变构IL-2穴88N→R雪的生物学活性奠定基础。方法分离人体T细胞经PHA刺激活化后,提取细胞的RNA为模板,逆转录构建cDNA文库,经套式PCR扩增出编码IL-2的基因,插入T-A载体后获得编码天然IL-2的克隆,核苷酸测序证实成功后,自行设计含有突变位点的引物,利用重组PCR技术,进行定点诱变构建基因变构IL-2穴88N→R雪的重组克隆熏DNA测序确认变构成功。将改构后的IL-2基因重组于原核pGEX-4T-2质粒上,转化宿主菌E.coli.DH5α中,经IPTG诱导后表达IL-2变构体,表达产物经SDS-PAGE电泳分析。结果获得了人类天然IL-2的编码基因克隆和基因变构IL-2的编码基因克隆,并将变构IL-2穴88N→R雪在大肠杆菌中获得了高效表达。结论IL-2基因的成功定点变构及其在原核生物中获得稳定高效的表达,为进一步在真核细胞中表达以及研究制备低毒、高效的新型基因变构IL-2药物奠定基础。     

PHLPP2在人胶质瘤中的表达及意义

目的研究PHLPP2在人正常脑组织以及脑胶质瘤组织中的表达及其临床意义。方法选取青岛大学附属医院与安丘人民医院神经外科自2014年12月至2016年10月间手术切除并经病理证实的人脑胶质瘤标本56例,其中I级7例,Ⅱ级19例,Ⅲ级21例,胶质母细胞瘤9例。另取20例因脑创伤行内减压术患者的正常脑组织标本作为对照。应用RT-PCR、Western-blotting分别检测各标本中PHLPP2m RNA和PHLPP2蛋白的表达。结果 RT-PCR和Western-blotting检测结果显示正常脑组织中PHLPP2 mRNA和PHLPP2蛋白表达最高,不同级别胶质瘤组织PHLPP2 mRNA和PHLPP2蛋白表达差异有统计学意义(P<0.05),且随着肿瘤病理级别的增高,胶质瘤组织中PHLPP2 mRNA和PHLPP2蛋白表达值降低,差异有统计学意义(P<0.05)。结论 PHLPP2在正常脑组织和不同级别的脑胶质瘤组织中都有表达,其表达值与肿瘤的病理分级呈负相关,PHLPP2可能作为一个肿瘤抑制基因在胶质瘤的发生、发展中起到关键性的作用。     

M2e与Qβ融合原核表达载体的构建与初步评价

目的 构建流感病毒M2基因(M2e)与Qβ的重组原核表达载体,并对Qβ-M2e病毒颗粒子(VLPs)进行免疫学评价,为预防性疫苗的研制打下基础.方法 通过分子生物学手段,将M2e同Qβ质粒载体连接构建重组原核表达载体,经酶切、测序鉴定后,将重组质粒转化大肠杆菌BL21中,密度梯度离心回收并纯化其表达产物Qβ-M2e.动...     

人白细胞介素24真核表达载体的构建及其在HepG2细胞中的表达

目的 构建人白细胞介素24(human interleukin-24,hIL-24)真核表达载体,并在HepG2细胞中稳定表达,为进一步研究其抗肿瘤作用奠定基础.方法 采用逆转录聚合酶链反应(RT-PCR),从植物血凝素活化的人外周血单个核细胞中克隆得到hIL-24基因目的 片段.应用DNA重组技术将IL-24PCR产物双酶切后定向克隆至真核表达载体pcDNA3.1(+),转化大肠杆菌DHSα获得重组载体,进行PCR、酶切及测序鉴定.应用脂质体将鉴定正确的重组质粒转染至HepG2细胞,用G418筛选稳定转染细胞株.采用RT-PCR检测稳定转染细胞HepG2中IL-24 mRNA的表达.结果 通过RT-PCR获得与预期大小一致约600 bp的IL-24基因片段;重组载体pcDNA3.1(+)-IL-24经PCR、双酶切及测序证实,IL-24 eDNA片段已正确插入真核表达载体中;在稳定转染的HepG2细胞株中可见到IL-24 mRNA表达.结论 成功构建了hIL-24真核表达载体pcDNA3.1(+)-IL-24,并获得了稳定转染该重组质粒的HepG2细胞株.     

Cigarette smoke extract combined with lipopolysaccharide reduces OCTN1/2 expression in human alveolar epithelial cells in vitro and rat lung in vivo under inflammatory conditions

Organic cation transporter 1/2 (OCTN1/2) play important roles in the transport of drugs related to pulmonary inflammatory diseases. Nevertheless, the involvement of inflammation induced by cigarette smoke extract (CSE) combined with lipopolysaccharide (LPS) in the regulation of OCTN1/2 is not fully understood. In this study, CSE combined with LPS was used to establish inflammation models in vitro and in vivo. Our study found that the expression of OCTN1/2 was downregulated in rat lung in vivo and in a human alveolar cell line in vitro after treatment with CSE and LPS compared with the control group, while the expression of inflammatory factors was upregulated. After treatment with ipratropium bromide (IB) or dexamethasone (DEX), the expression of OCTN1/2 was upregulated compared with that in the CSE-LPS model group, while the expression of inflammatory factors was significantly downregulated. After administration of the NF-κB inhibitor PDTC on the basis of the inflammatory status, the expression of OCTN1/2 was upregulated in the treated group compared with the CSE-LPS model group, while the expression of phospho-p65, phospho-IκBα and inflammatory factors was significantly downregulated. We further added the NF-κB agonist HSP70 and found a result that the exact opposite of that observed with PDTC. Our findings show that CSE combined with LPS can downregulate the expression of OCTN1/2 under inflammatory conditions, and that the downregulation of OCTN1/2 expression may partially occur via the NF-κB signaling pathway.     

胞质蛋白NOD2重组腺病毒载体的构建

Objective To construct adenovirus vector containing the NOD2 gene for studying therapeutic inflammation disease. Methods NOD2 was obtained from human CoCa2 DNA based on Adopt molecule clone tech-nique, and then was cloned into plasmid pcDNA3.1 (+) and further cloned into plasmid pShutde-CMV ,pShuttleC-MV-NOD2 with double digestion of PI- Kpn Ⅰ and Ⅰ- Not Ⅰ. The recombinant adenoviral plasmid was identified and transferred into the adenoviral packaging cell HEK293 by lipofectamine 2000 mediated gent transfer method. The recombinant adenovius was confirmed by polymerase chain reaction (PCR). Results The recombinant pAdeno-NOD2 was correctly constructed and confirmed by restriction endonuclease analysis. The transferred HEK 293 cells were lysed by freezethawingto obtaining the recombinant adenovirus in the lysate. The PCR product of the lysate confirmed the presence ofrecombinant adenovirus. Conclusion The recombinant adenovims containing the NOD2 gene can be successfully constructed, which provides the further foundation of NOD2 gene therapy for inflammation disease.     

胞质蛋白NOD2重组腺病毒载体的构建

Objective To construct adenovirus vector containing the NOD2 gene for studying therapeutic inflammation disease. Methods NOD2 was obtained from human CoCa2 DNA based on Adopt molecule clone tech-nique, and then was cloned into plasmid pcDNA3.1 (+) and further cloned into plasmid pShutde-CMV ,pShuttleC-MV-NOD2 with double digestion of PI- Kpn Ⅰ and Ⅰ- Not Ⅰ. The recombinant adenoviral plasmid was identified and transferred into the adenoviral packaging cell HEK293 by lipofectamine 2000 mediated gent transfer method. The recombinant adenovius was confirmed by polymerase chain reaction (PCR). Results The recombinant pAdeno-NOD2 was correctly constructed and confirmed by restriction endonuclease analysis. The transferred HEK 293 cells were lysed by freezethawingto obtaining the recombinant adenovirus in the lysate. The PCR product of the lysate confirmed the presence ofrecombinant adenovirus. Conclusion The recombinant adenovims containing the NOD2 gene can be successfully constructed, which provides the further foundation of NOD2 gene therapy for inflammation disease.     

胞质蛋白NOD2重组腺病毒载体的构建

Objective To construct adenovirus vector containing the NOD2 gene for studying therapeutic inflammation disease. Methods NOD2 was obtained from human CoCa2 DNA based on Adopt molecule clone tech-nique, and then was cloned into plasmid pcDNA3.1 (+) and further cloned into plasmid pShutde-CMV ,pShuttleC-MV-NOD2 with double digestion of PI- Kpn Ⅰ and Ⅰ- Not Ⅰ. The recombinant adenoviral plasmid was identified and transferred into the adenoviral packaging cell HEK293 by lipofectamine 2000 mediated gent transfer method. The recombinant adenovius was confirmed by polymerase chain reaction (PCR). Results The recombinant pAdeno-NOD2 was correctly constructed and confirmed by restriction endonuclease analysis. The transferred HEK 293 cells were lysed by freezethawingto obtaining the recombinant adenovirus in the lysate. The PCR product of the lysate confirmed the presence ofrecombinant adenovirus. Conclusion The recombinant adenovims containing the NOD2 gene can be successfully constructed, which provides the further foundation of NOD2 gene therapy for inflammation disease.     

胞质蛋白NOD2重组腺病毒载体的构建

Objective To construct adenovirus vector containing the NOD2 gene for studying therapeutic inflammation disease. Methods NOD2 was obtained from human CoCa2 DNA based on Adopt molecule clone tech-nique, and then was cloned into plasmid pcDNA3.1 (+) and further cloned into plasmid pShutde-CMV ,pShuttleC-MV-NOD2 with double digestion of PI- Kpn Ⅰ and Ⅰ- Not Ⅰ. The recombinant adenoviral plasmid was identified and transferred into the adenoviral packaging cell HEK293 by lipofectamine 2000 mediated gent transfer method. The recombinant adenovius was confirmed by polymerase chain reaction (PCR). Results The recombinant pAdeno-NOD2 was correctly constructed and confirmed by restriction endonuclease analysis. The transferred HEK 293 cells were lysed by freezethawingto obtaining the recombinant adenovirus in the lysate. The PCR product of the lysate confirmed the presence ofrecombinant adenovirus. Conclusion The recombinant adenovims containing the NOD2 gene can be successfully constructed, which provides the further foundation of NOD2 gene therapy for inflammation disease.     

胞质蛋白NOD2重组腺病毒载体的构建

目的构建人NOD2腺病毒表达载体。方法采用分子克隆技术,从CoCa2细胞DNA中PCR扩增NOD2片段,经pcDNA3．1克隆到穿梭质粒pShuttle—CMV,以KpnⅠ和NotⅠ双酶切重组穿梭质粒,经电穿孔、抗性筛选,重组成pAdCMV-NOD2腺病毒质粒,经酶切鉴定正确后,在HEK293细胞中包装成为重组rvAdCMV-NOD2腺病毒,并进行PCR鉴定测定。结果成功扩增目的基因并鉴定,重组穿梭质粒pShuttle-CMV-NOD2鉴定,经酶切鉴定证实重组腺病毒质粒构建成功。结论腺病毒载体应用广泛,细菌体内同源重组腺病毒pAdCMV-NOD2合成效率高,为炎症的基因治疗研究奠定基础。     

E2F1基因真核表达载体的构建及其对CD2 AP启动子的影响

目的构建E2F1基因真核表达质粒,并初步探讨E2F1对CD2相关蛋白(CD2AP)启动子的作用。方法 RT-PCR扩增E2F1基因,构建含E2F1基因的重组真核表达质粒,重组质粒转染人胚肾HEK-293细胞。Western blot检测E2F1蛋白表达;双荧光素酶报告基因检测E2F1过表达后人CD2AP启动子的活性。结果核酸序列分析及Western blot结果证实,成功构建含E2F1基因的重组真核表达质粒;过表达E2F1能增强CD2AP启动子的活性。结论 E2F1编码基因在HEK-293细胞中获得正确表达,且E2F1蛋白可促进人CD2AP启动子的转录活性。